[go: up one dir, main page]

HK1246156B - Fgf21衍生物及其用途 - Google Patents

Fgf21衍生物及其用途

Info

Publication number
HK1246156B
HK1246156B HK18105587.8A HK18105587A HK1246156B HK 1246156 B HK1246156 B HK 1246156B HK 18105587 A HK18105587 A HK 18105587A HK 1246156 B HK1246156 B HK 1246156B
Authority
HK
Hong Kong
Prior art keywords
fgf21 derivatives
fgf21
derivatives
Prior art date
Application number
HK18105587.8A
Other languages
English (en)
Inventor
Birgit Wieczorek
Tina Møller Tagmose
Kristian Sass-Ørum
Birgitte Andersen
Jørgen Olsen
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of HK1246156B publication Critical patent/HK1246156B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK18105587.8A 2014-12-23 2018-04-30 Fgf21衍生物及其用途 HK1246156B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14199935 2014-12-23
PCT/EP2015/080969 WO2016102562A1 (en) 2014-12-23 2015-12-22 Fgf21 derivatives and uses thereof

Publications (1)

Publication Number Publication Date
HK1246156B true HK1246156B (zh) 2020-03-27

Family

ID=52130150

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18105587.8A HK1246156B (zh) 2014-12-23 2018-04-30 Fgf21衍生物及其用途

Country Status (25)

Country Link
US (3) US9744213B2 (zh)
EP (1) EP3236991B1 (zh)
JP (1) JP6727210B2 (zh)
KR (1) KR102427527B1 (zh)
CN (1) CN107108709B (zh)
AR (1) AR103246A1 (zh)
AU (1) AU2015371056B2 (zh)
CA (1) CA2972128A1 (zh)
DK (1) DK3236991T3 (zh)
ES (1) ES2742503T3 (zh)
HK (1) HK1246156B (zh)
HR (1) HRP20191292T1 (zh)
HU (1) HUE044783T2 (zh)
IL (1) IL252438B (zh)
MX (1) MX2017007458A (zh)
MY (1) MY181181A (zh)
PL (1) PL3236991T3 (zh)
PT (1) PT3236991T (zh)
RS (1) RS59154B1 (zh)
RU (1) RU2729011C2 (zh)
SA (1) SA517381673B1 (zh)
SI (1) SI3236991T1 (zh)
TW (2) TWI708781B (zh)
WO (1) WO2016102562A1 (zh)
ZA (1) ZA201703768B (zh)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102433503B1 (ko) 2016-05-24 2022-08-18 노보 노르디스크 에이/에스 Mic-1 화합물 및 이것의 사용
CN106421753A (zh) * 2016-10-19 2017-02-22 哈尔滨医科大学 重组人成纤维细胞生长因子‑21在制备预防和治疗缺血性心律失常药物中的应用
TWI710377B (zh) 2017-05-23 2020-11-21 丹麥商諾佛 儂迪克股份有限公司 Ｍｉｃ－１化合物及其用途
IL272987B (en) 2017-09-04 2022-08-01 89Bio Ltd Mutant fgf-21 peptide conjugates and uses thereof
PE20210632A1 (es) 2018-07-03 2021-03-23 Bristol Myers Squibb Co Formulaciones de fgf-21
US11427623B1 (en) 2019-05-28 2022-08-30 89Bio Ltd. Methods of treatment using mutant FGF-21 peptide conjugates
CN115322794A (zh) 2020-01-11 2022-11-11 北京质肽生物医药科技有限公司 Glp-1和fgf21的融合蛋白的缀合物
JP2024517329A (ja) 2021-05-11 2024-04-19 サイトカイ・ファーマ・アーペーエス インターロイキン－２２の治療的誘導体
EP4089108A1 (en) 2021-05-11 2022-11-16 CytoKi Pharma ApS Therapeutic derivatives of interleukin-22
KR102631925B1 (ko) * 2021-06-10 2024-02-01 토드제약 주식회사 신규 fgf21 변이체 개발 및 이의 생산기법과 용도
JP2024527613A (ja) * 2021-07-14 2024-07-25 ベイジン キューエル バイオファーマシューティカル カンパニー，リミテッド 代謝性障害のための融合ポリペプチド
JP2024531980A (ja) * 2021-09-08 2024-09-03 リートー ラボラトリーズ カンパニー リミテッド Ｆｇｆ２１変異タンパク質及びその応用
WO2024008904A2 (en) 2022-07-08 2024-01-11 Novo Nordisk A/S Highly potent isvd compounds capable of substituting for fviii(a)
US12098400B2 (en) 2022-07-08 2024-09-24 Novo Nordisk A/S Highly potent ISVD compounds capable of substituting for FVIII(A)
WO2024199734A2 (en) 2023-03-30 2024-10-03 Novo Nordisk A/S Fusion compounds and uses thereof
WO2024235802A1 (en) * 2023-05-12 2024-11-21 Novo Nordisk A/S Long-acting growth hormone receptor antagonist and use thereof
WO2025056575A1 (en) 2023-09-11 2025-03-20 Novo Nordisk A/S Anti il-6 domain antibodies
CN118307684B (zh) * 2024-06-11 2024-10-18 北京志道生物科技有限公司 一种经脂肪酸链修饰的glp-1-fgf21融合蛋白及其制备方法和应用

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
JP3149958B2 (ja) 1996-08-30 2001-03-26 ノボ ノルディスク アクティーゼルスカブ Ｇｌｐ―１誘導体
WO2003011213A2 (en) 2001-07-30 2003-02-13 Eli Lilly And Company Method for treating diabetes and obesity
EP1329227A1 (en) 2002-01-22 2003-07-23 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Diagnostic conjugate useful for intercellular imaging and for differentiating between tumor- and non-tumor cells
ES2371072T3 (es) 2003-06-12 2011-12-27 Eli Lilly And Company Proteínas de fusión análogas de glp-1.
WO2005027978A2 (en) 2003-09-19 2005-03-31 Novo Nordisk A/S Albumin-binding derivatives of therapeutic peptides
JP2007537981A (ja) 2003-09-19 2007-12-27 ノボ　ノルディスク　アクティーゼルスカブ 新規の血漿タンパク質親和性タグ
CN1890371A (zh) * 2003-12-10 2007-01-03 伊莱利利公司 成纤维细胞生长因子的21突变蛋白
BRPI0417684A (pt) 2003-12-18 2007-03-20 Novo Nordisk As composto, composição farmacêutica, e, uso de um composto
US20070265200A1 (en) 2004-03-17 2007-11-15 Eli Lilly And Company Glycol Linked Fgf-21 Compounds
EP1751184B1 (en) 2004-05-13 2009-09-30 Eli Lilly And Company Fgf-21 fusion proteins
GB0412181D0 (en) 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
JP2008507477A (ja) * 2004-07-08 2008-03-13 ノボ　ノルディスク　アクティーゼルスカブ ポリペプチド延長タグ
AU2005283025B2 (en) 2004-09-02 2011-06-30 Eli Lilly And Company Muteins of fibroblast growth factor 21
WO2006028714A1 (en) 2004-09-02 2006-03-16 Eli Lilly And Company Muteins of fibroblast growth factor 21
ES2566670T3 (es) 2004-10-29 2016-04-14 Ratiopharm Gmbh Remodelación y glucopegilación del factor de crecimiento de fibroblastos (FGF)
WO2006065582A2 (en) 2004-12-14 2006-06-22 Eli Lilly And Company Muteins of fibroblast growth factor 21
EP1846019A2 (en) 2005-01-21 2007-10-24 Eli Lilly And Company Method for treating cardiovascular disease
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
US20100022446A1 (en) 2007-01-18 2010-01-28 Novo Nordisk A/S Use of Peptides in Combination with Surgical Intervention for the Treatment of Obesity
KR20140012199A (ko) 2007-03-30 2014-01-29 암브룩스, 인코포레이티드 변형된 ｆｇｆ-21 폴리펩티드 및 그 용도
CN101663046B (zh) 2007-03-30 2017-07-28 Ambrx公司 经修饰fgf‑21多肽和其用途
ES2646614T3 (es) 2007-08-03 2017-12-14 Eli Lilly And Company Uso de un compuesto de FGF 21 y un compuesto de GLP 1 para el tratamiento de la obesidad
ES2532116T3 (es) 2007-09-05 2015-03-24 Novo Nordisk A/S Péptidos derivados con A-B-C-D y sus usos terapéuticos
US20100317057A1 (en) 2007-12-28 2010-12-16 Novo Nordisk A/S Semi-recombinant preparation of glp-1 analogues
CN100587073C (zh) 2008-03-24 2010-02-03 吉林农大生物反应器工程有限公司 人成纤维细胞生长因子-21的重组表达
JOP20190083A1 (ar) 2008-06-04 2017-06-16 Amgen Inc بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
UA105016C2 (uk) 2008-10-10 2014-04-10 Амген Інк. Fgf21 мутанти і їх застосування
WO2010065439A1 (en) 2008-12-05 2010-06-10 Eli Lilly And Company Variants of fibroblast growth factor 21
MX2011007544A (es) * 2009-01-23 2011-08-12 Novo Nordisk As Derivados de factor de crecimiento de fibroblastos 21 (fgf21) con ligante de albumina a-b-c-d-e- y su uso.
PL3248610T3 (pl) 2009-05-05 2024-04-02 Amgen Inc. Mutanty fgf21 i ich zastosowania
WO2010129600A2 (en) 2009-05-05 2010-11-11 Amgen Inc. Fgf21 mutants and uses thereof
US20120035099A1 (en) * 2009-06-11 2012-02-09 Novo Nordisk A/S Fgf21 analogues and derivatives
US20120172298A1 (en) * 2009-06-11 2012-07-05 Novo Nordisk A/S Glp-1 and fgf21 combinations for treatment of diabetes type 2
WO2011154349A2 (en) * 2010-06-08 2011-12-15 Novo Nordisk A/S Fgf21 analogues and derivatives
EP2595647A1 (en) * 2010-07-20 2013-05-29 Novo Nordisk A/S N-terminal modified fgf21 compounds
JP2014526441A (ja) * 2011-08-31 2014-10-06 アムジエン・インコーポレーテツド １型糖尿病の治療における使用のためのｆｇｆ２１
AU2013311777B2 (en) * 2012-09-07 2018-02-01 Sanofi Fusion proteins for treating a metabolic syndrome
SG11201504815QA (en) * 2012-12-27 2015-07-30 Ngm Biopharmaceuticals Inc Methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases

Also Published As

Publication number Publication date
HRP20191292T1 (hr) 2019-10-18
AU2015371056A1 (en) 2017-06-15
TWI681966B (zh) 2020-01-11
MX2017007458A (es) 2017-08-10
US9744213B2 (en) 2017-08-29
AU2015371056B2 (en) 2020-06-25
DK3236991T3 (da) 2019-08-26
IL252438A0 (en) 2017-07-31
HUE044783T2 (hu) 2019-11-28
CN107108709B (zh) 2021-12-14
CA2972128A1 (en) 2016-06-30
MY181181A (en) 2020-12-21
ES2742503T3 (es) 2020-02-14
TWI708781B (zh) 2020-11-01
AR103246A1 (es) 2017-04-26
US20180140673A1 (en) 2018-05-24
RU2729011C2 (ru) 2020-08-03
SI3236991T1 (sl) 2019-09-30
JP6727210B2 (ja) 2020-07-22
US10124039B2 (en) 2018-11-13
US9895417B2 (en) 2018-02-20
EP3236991B1 (en) 2019-06-19
PT3236991T (pt) 2019-09-06
ZA201703768B (en) 2020-05-27
RS59154B1 (sr) 2019-10-31
BR112017011552A2 (pt) 2018-02-14
JP2018505146A (ja) 2018-02-22
PL3236991T3 (pl) 2019-12-31
CN107108709A (zh) 2017-08-29
TW201632545A (zh) 2016-09-16
RU2017125050A (ru) 2019-01-25
SA517381673B1 (ar) 2020-10-29
WO2016102562A1 (en) 2016-06-30
IL252438B (en) 2021-09-30
KR102427527B1 (ko) 2022-08-01
RU2017125050A3 (zh) 2019-06-06
KR20170095256A (ko) 2017-08-22
US20170354713A1 (en) 2017-12-14
EP3236991A1 (en) 2017-11-01
TW202012431A (zh) 2020-04-01
US20170182124A1 (en) 2017-06-29

Similar Documents

Publication Publication Date Title
IL279663A (en) N4-hydroxycytidine, history and related antiviral uses
HK1246156B (zh) Fgf21衍生物及其用途
HK1225383A1 (zh) 二氮雜環庚烷衍生物及其用途
HK1231471A1 (zh) -雜芳氧基-和 芳氧基-喹啉- -甲酰胺及其用途
IL252216A0 (en) Difluoromethyl-aminopyridines and difluoromethyl-aminopyrimidines
IL247822A0 (en) History of Tubolisin
PL3152226T3 (pl) Modyfikowane cyklopentapeptydy i ich zastosowania
SG11201609490QA (en) Polymer-flavonoid conjugate and uses thereof
HUE050450T2 (hu) Fluoralkil-fluorén-származékok
PT3166945T (pt) Derivados de triazolopirimidinona ou de triazolopiridinona inovadores e utilização dos mesmos
AP2016009545A0 (en) Naphthyridinedione derivatives
AP2016009530A0 (en) Cycloalkyl-linked diheterocycle derivatives
IL254241A0 (en) Etv2 and its uses
HK1232211A1 (zh) 二甲基吡啶胺衍生物及其醫藥用途
IL251289B (en) New peptide derivatives and their use
AU358328S (en) Pants